This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.–5. (Canceled)

6. (Previously Presented) A method of claim 38 wherein B of Formula I is an unsubstituted phenyl group, an unsubstituted pyridyl group, an unsubstituted pyrimidinyl, a phenyl group substituted by one or more substituents which are halogen or W_n wherein W is as defined in claim 2 and n is 0-3, a pyrimidinyl group substituted by one or more substituents which are halogen or W_n wherein, W is as defined in claim 2 and n is 0-3, or a substituted pyridyl group substituted by one or more substituents which are halogen or W_n wherein W is as defined in claim 2 and n is 0-3.

7. (Previously Presented) A method of claim 91 wherein B of Formula I is a substituted phenyl group, a substituted pyrimidinyl group, or substituted pyrridyl group substituted 1 to 3 times by 1 or more substituents which are -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkoxy or phenyl substituted by halogen up to per-halosubstitution.

8. (Canceled)

9. (Previously Presented) A method of claim 91, wherein L, the 6 member cyclic structure bound directly to D, is a substituted phenyl, unsubstituted phenyl, substituted pyrimidinyl, unsubstituted pyrimidinyl, substituted pyridyl or unsubstituted pyridyl group.

10. (Previously Presented) A method of claim 38 wherein said substituted cyclic moiety L^1 comprises pyridinyl..

11. (Previously Presented) A method of claim 39, wherein said substituted cyclic moiety L^1 is pyridinyl.

12. (Canceled)

13. **(Previously Presented)** A method of claim 6, wherein said substituted cyclic moiety L^1 is pyridinyl.

14. **(Canceled)**

15. **(Previously Presented)** A method of claim 7, wherein said substituted cyclic moiety L^1 is pyridinyl.

16.–37. **(Canceled)**

38. **(Previously Presented)** A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-$(M\text{-}L^1)_q$, where L is a 6 membered aryl moiety or a 6 membered hetaryl moiety bound directly to D, L^1 comprises a substituted cyclic moiety having 5-6 members, q is an integer of from 1-3; and each cyclic structure of L and L^1 contains 0-4 heteroatoms which are nitrogen, oxygen or sulfur, and

B is a substituted or unsubstituted, phenyl, pyridyl or pyrimidinyl group,

wherein L^1 is substituted by at least one substituent which is of $-SO_2R_x$, $-C(O)R_x$ or $-C(NR_y)R_z$,

R_y is hydrogen or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkenoyl, $C_{6\text{-}12}$ aryl, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are O, N or S, $C_{3\text{-}10}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{7\text{-}24}$ aralkyl, C_7-C_{24} alkaryl, substituted $C_{1\text{-}10}$ alkyl, substituted $C_{1\text{-}10}$ alkoxy, substituted $C_{3\text{-}10}$ cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted $C_{6\text{-}12}$ aryl, substituted $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, substituted $C_{7\text{-}24}$ aralkyl, or substituted $C_{7\text{-}24}$ alkaryl, R_z is hydrogen or substituted by halogen up to per-halosubstitution, hydroxy, $C_{1\text{-}10}$ alkyl, $C_{3\text{-}12}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{1\text{-}10}$ alkoxy, $C_{6\text{-}12}$ aryl, $C_{1\text{-}6}$ halosubstituted alkyl up to per-

halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, or R_x is independently chosen from the R_z moieties or is r NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkenoyl, $C_{6\text{-}12}$ aryl, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{3\text{-}10}$ cycloalkyl having 0-3 heteroatoms which are from N, S or O, $C_{7\text{-}24}$ aralkyl, C_7-C_{24} alkaryl, substituted $C_{1\text{-}10}$ alkyl, substituted $C_{1\text{-}10}$ alkoxy, substituted $C_{3\text{-}10}$ cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted $C_{6\text{-}12}$ aryl, substituted $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, substituted $C_{7\text{-}24}$ aralkyl, or substituted $C_{7\text{-}24}$ alkaryl,

where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, $C_{1\text{-}10}$ alkyl, $C_{3\text{-}12}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms selected from N, S and O, $C_{1\text{-}10}$ alkoxy, $C_{6\text{-}12}$ aryl, $C_{1\text{-}6}$ halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, or

iii) $-OSi(R_f)_3$ where R_f is hydrogen or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $C_{3\text{-}10}$ cycloalkyl, $C_{2\text{-}10}$ alkenyl, $C_{1\text{-}10}$ alkenoyl, $C_{6\text{-}12}$ aryl, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{3\text{-}10}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{7\text{-}24}$ aralkyl, C_7-C_{24} alkaryl, substituted $C_{1\text{-}10}$ alkyl, substituted $C_{1\text{-}10}$ alkoxy, substituted $C_{3\text{-}10}$ cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted $C_{6\text{-}12}$ aryl, substituted $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, substituted $C_{7\text{-}24}$ aralkyl, or substituted $C_{7\text{-}24}$ alkaryl,

where R_f is a substituted group it is substituted by halogen up to per-halosubstitution, hydroxy, $C_{1\text{-}10}$ alkyl, $C_{3\text{-}12}$ cycloalkyl having 0-3 heteroatoms which are N, S or O, $C_{3\text{-}12}$ hetaryl having 1-3 heteroatoms which are N, S or O, $C_{1\text{-}10}$ alkoxy, $C_{6\text{-}12}$ aryl, $C_{1\text{-}6}$ halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N,

S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O substituted by halogen, or hydroxy or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the 5-7 member heterocyclic structure is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are halogen, hydroxy C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the C_1-C_5 divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are

N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are halogen, up to per-halosubstitution, and W_n, where n is 0-3;

wherein each W is independently -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, C_1 -C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

wherein W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

wherein Q is -O-, -S-, $-N(R^7)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^7)-$, $-O(CH_2)_m-$ CHX^a-, $-CX^a{}_2-$, $-S-(CH_2)_m-$ or $-N(R^7)(CH_2)_m-$, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are nitrogen, oxygen or sulfur, which is optionally substituted by halogen, up to per-halosubstitution, and is optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$-NR^7R^7, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms selected from O, N and S, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3

heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstituted, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

and

wherein M is one or more bridging groups which are -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or -N(R^7)$(CH_2)_m$-, where m= 1-3, and X^a is halogen.

39. (Previously Presented) A method for the treatment of cancerous cell growth mediated by RAF kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-L^1)$_q$, where L is a substituted or unsubstituted phenyl moiety bound directly to D, L^1 comprises a substituted phenyl, pyridinyl or pyrimidinyl moiety, q is an integer of from 1-3; and

B is a substituted or unsubstituted phenyl or pyridinyl group bound directly to D,

wherein L^1 is substituted by one or more substituents which are, -C(O)R_x or -C(NR_y) R_z,

R_y is hydrogen or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_y is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

R_z is hydrogen or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

R_x is independently chosen from the R_z moieties or is NR_aR_b where R_a and R_b are

a) independently

i) hydrogen,

ii) C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_x is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6}

halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

iii) $-OSi(R_f)_3$ where R_f is hydrogen or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where R_f is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl, or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O substituted by halogen, hydroxy or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the 5-7 member heterocyclic structure is substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl

having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are halogen, hydroxy, or a C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where the substituent on the C_1-C_5 divalent alkylene is a substituted group, it is substituted by halogen up to per-halosubstituted, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are halogen, up to per-halosubstitution, or W_n, where n is 0-3;

wherein each W is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, -Q-Ar, or C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S or O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where W is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6}

halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl;

wherein Q is -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or -N(R^7)$(CH_2)_m$-, where m= 1-3, and X^a is halogen;

Ar is a 5- or 6-member aromatic structure containing 0-2 heteroatoms which are nitrogen, oxygen or sulfur, which is optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently -CN, -CO_2R^7, -C(O)R^7, -C(O)NR^7R^7, -NO_2, -OR^7, - SR^7 -NR^7R^7, -NR^7C(O)OR^7, -NR^7C(O)R^7, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{3-10} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{7-24} aralkyl, C_7-C_{24} alkaryl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_{3-10} cycloalkyl, having 0-3 heteroatoms which are N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, substituted C_{7-24} aralkyl, or substituted C_{7-24} alkaryl,

where Z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S and O, C_{3-12} hetaryl having 1-3 heteroatoms which are N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halosubstituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl having 0-3 heteroatoms which are N, S or O, up to per-halosubstituted cycloalkyl, or halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted heteroaryl; and

wherein M is one or more bridging groups which are -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or -N(R^7)$(CH_2)_m$-, where m= 1-3, X^a is halogen.

40.–43 (Canceled)

44. (Previously Presented) A method as in claim 38 wherein substituents for B and L and additional substituents for L^1, are C_1-C_{10} alkyl up to per-halosubstituted -C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy or up to per-halosubstituted C_1-C_{10} alkoxy.

45. **(Previously Presented)** A method as in claim 39 wherein substituents for B and L and additional substituents for L^1, are C_1-C_{10} alkyl up to per-halosubstituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy or up to per-halosubstituted C_1-C_{10} alkoxy.

46. **(Previously Presented)** A method of claim 38 wherein L^1 is pyridinyl substituted by $C(O)R_x$ or SO_2R_x.

47. **(Previously Presented)** A method of claim 39 wherein L^1 is pyridinyl substituted by $C(O)R_x$ or SO_2R_x.

48. **(Previously Presented)** A method of claim 46 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen C_1-C_{10} alkyl, $C_{3\text{-}10}$ cycloalkyl, C_6-C_{12} aryl, substituted $C_{1\text{-}10}$ alkyl, substituted $C_{3\text{-}10}$ cycloalkyl or substituted C_6-C_{12} aryl

where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy or $C_{1\text{-}10}$ alkyl,

49. **(Previously Presented)** A method of claim 47 wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or C_1-C_{10} alkyl, $C_{3\text{-}10}$ cycloalkyl or $C_{6\text{-}12}$ aryl.

50.–52. **(Canceled)**

53. **(Previously Presented)** A method of claim 38 wherein the compound Formula I is a pharmaceutically acceptable salt which is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing a cation which is an alkali metal cation, an alkaline earth metal cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

54. **(Previously Presented)** A method of claim 39 wherein the compound of Formula I is a pharmaceutically acceptable salt which is

a) a basic salt of an organic acid or an and inorganic acid which is hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, trifluorosulphonic acid, benzenesulfonic acid, p-toluene sulphonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or an

b) an acid salt of an organic or inorganic base containing a cation which is an alkali metal cation, an alkaline earth metal cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

55.–65. **(Canceled)**

66. **(Previously Presented)** A method for the treatment of a cancerous cell growth mediated by raf kinase in a human or other mammal in need thereof, comprising administering to a human or other mammal in need thereof a compound which is a

3-tert butyl phenyl urea;

5-tert butyl-2-methoxyphenyl urea;

5-(trifluoromethyl)-2 phenyl urea;

3-(trifluoromethyl) –4 chlorophenyl urea;

3-(trifluoromethyl)-4-bromophenyl urea; or

5-(trifluoromethyl)-4-chloro-2 methoxyphenyl urea.

67. **(Canceled)**

68.–69. **(Canceled)**

70. **(Previously Presented)** A method as in claim 38 for the treatment of carcinomas, myeloid disorders or adenomas.

71. **(Previously Presented)** A method as in claim 39 for the treatment of carcinomas, myeloid disorders or adenomas.

72. (Canceled)

73. (Canceled)

74. (Canceled)

75. (Previously Presented) A method as in claim 38 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

76. (Previously Presented) A method as in claim 39 for the treatment of carcinoma of the lung, pancreas, thyroid, bladder or colon.

77. (Canceled)

78. (Canceled)

79. (Canceled)

80. (Previously Presented) A method as in claim 38 for the treatment of myeloid leukemia or villous colon adenomas.

81. (Previously Presented) A method as in claim 39 for the treatment of myeloid leukemia or villous colon adenomas.

82. (Canceled)

83. (Canceled)

84.–87. (Canceled)

88. (Previously Presented) A method for the treatment of cancerous cell growth in a human or other mammal comprising administering to a human or other mammal in need thereof:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

89. **(Previously Presented)** A method for the treatment of cancerous cell growth mediated by raf kinase in a human or other mammal comprising administering to a human or other mammal in need thereof:

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

90. **(Previously Presented)** A method for the treatment of a raf mediated disorder in a human or other mammal which comprises administering to a human or other mammal in need thereof;

N-(2-methoxy-5-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea,

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or

N-(2-methoxy-4-chloro-5-(trifluoromethyl)phenyl)-*N'*-(3-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea

in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

91. **(Previously Presented)** A method for treatment of a solid tumor carcinoma of the lung, carcinoma of the pancreas, carcinoma of the thyroid carcinoma of the bladder, carcinoma of the colon, myeloid leukemia or villous colon adenomas in a human or other mammal, comprising administering to a human or other mammal in need thereof a pharmaceutical composition comprising a compound of Formula I:

A-D-B (I)

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein

D is -NH-C(O)-NH-,

A is a substituted moiety of the formula:

-L-M-L^1

wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or ranched haloalkyl up to per-halosubstituted, C_1-C_3 alkoxy, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano or nitro;

(ii) a 5 membered monocyclic heteroaryl group, having 1-2 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to per-halosubstitution, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; or

(iii) a 6 membered monocyclic heteroaryl group having 1-4 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents, which are, independently, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to per-

halosubstitution, C_1-C_3 alkoxy, C_1-C_3 haloalkoxy up to per-halosubstituted alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano or nitro;

L^1 comprises a substitution cyclic moiety which is

(i) phenyl, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are independently O, N and S, optionally substituted with 1-3 substituents which are independently R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are independently, O, N and S, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(v) saturated and partially saturated C_3-C_6 monocyclic carbocyclic moieties optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(vi) saturated and partially saturated C_8-C_{10} bicyclic carbocyclic moieties, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(vii) saturated and partially saturated 5 and 6 membered monocyclic heterocyclic moieties, having 1-3 heteroatoms which are independently, O, N and S, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro; or

(viii) saturated and partially saturated 8 to 10 membered bicyclic heterocyclic moieties, having 1-6 heteroatoms which are independently, O, N and S, optionally substituted with 1-3 substituents which are independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$. $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

wherein L^1 is substituted by one or more substituents which are $-SO_2R_x$, $-C(O)R_x$ or $-C(NR_y)R_z$,

wherein R_z is

a) independently hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 which are N, S or O heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{7-24} alkaryl, C_{7-24} aralkyl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_6-C_{14} aryl, substituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl

where R_z is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl up to per-halosubstituted per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C_3-C_{12} hetaryl up to per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted aralkyl, or halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted alkaryl,

wherein R_x is independently chosen from R_z moieties or is NR_aR_b and R_a and R_b are

a) independently chosen from the hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{3-10} cycloalkyl having 0-3 which are N, S or O heteroatoms, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_3-C_{12} hetaryl having 1-3 heteroatoms which are N, S or O, C_{7-24} alkaryl, C_{7-24} aralkyl, substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted C_6-C_{14} aryl, substituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms which are N, S or O, substituted C_{3-12} hetaryl having 1-3 heteroatoms which are N, S or O, substituted C_{7-24} alkaryl or substituted C_7-C_{24} aralkyl where R_a or R_b is a substituted group, it is substituted by halogen up to per-halosubstitution, hydroxy, C_{1-10} alkyl, C_{3-12} cycloalkyl having 0-3 heteroatoms which are N, S or O, C_{3-12} hetaryl having 1-3 heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, C_{1-6} halo substituted alkyl up to per-halosubstituted alkyl, C_6-C_{12} halosubstituted aryl up to per-halosubstituted aryl, C_3-C_{12} halosubstituted cycloalkyl up to per-halosubstituted per-halo cycloalkyl having 0-3 heteroatoms which are N, S or O, halosubstituted C_3-C_{12} hetaryl up to

per-halosubstituted hetaryl having 1-3 heteroatoms which are N, S or O, halosubstituted C_7-C_{24} aralkyl up to per-halosubstituted aralkyl, halosubstituted C_7-C_{24} alkaryl up to per-halosubstituted alkaryl, or is

b) combined together to form a 5-7 member heterocyclic structure of 1-3 heteroatoms which are N, S or O, optionally substituted by halogen hydroxy or C_{1-10} alkyl; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted

C_1-C_5 divalent alkylene group bound to the moiety L^1 to form a cyclic structure with at least 5 members, wherein the substituents of the substituted

C_1-C_5 divalent alkylene group are halogen hydroxy, or C_{1-10} alkyl;

wherein M is one or more bridging groups which are -O-, -S-, -N(R^7)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^7)-, -O$(CH_2)_m$- CHX^a-, -CX^a_2-, -S-$(CH_2)_m$- or -N(R^7)$(CH_2)_m$-, where m= 1-3, and X^a is halogen and.

B is:

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$ halogen, cyano, or nitro;

(ii) naphthyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

(iii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(iv) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

each R_y is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with halogen up to per-halosubstitution,

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 halogen substituents,

(d) C_3-C_6 cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each R^7, and $R^{7'}$, is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy;

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 substituents which are, independently, C_1-C_5, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 l alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(f) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy, hydroxy or halogen; and

(g) up to per–halosubstituted C_1-C_5, and where not per-halosubstituted, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 alkyl, up to per-halosubstituted C_1-C_5 alkyl, C_1-C_3 alkoxy or hydroxy.

92. **(Previously Presented)** A method as in claim 91 wherein M is one or more bridging groups is -O-, -S-, -N(R^7)-, -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -(CH_2)N(R^7)-, -O(CH_2)-, -CHF-, -CF_2-, -S-(CH_2)- and -N(R^7)(CH_2)-, -C(O)CH_2-, -CH_2OC(O)-, -C(O)OCH_2-, -C(O)N(R^7)CH_2-, -N(R^7)C(O)CH_2-, or -N(R^7)C(O) OCH_2-, where R^7 is as defined in claim 91.

93. **(Previously Presented)** A method as in claim 91 wherein B of Formula I is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(iii) pyrimidinyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro.

94. **(Previously Presented)** A method as in claim 91 wherein B of Formula I is phenyl, or pyridinyl l, substituted 1 to 3 times by one or more substituents which are independently -CN, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -OH, up to per-halosubstituted C_1-C_6 alkyl, up to per halo substituted C_1-C_6 alkoxy or phenyl substituted by halogen up to per-halosubstitution.

95. **(Previously Presented)** A method as in claim 94, wherein L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^1, OR^1, NR^1R^2, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, $NR^1C(O)R^2$, $NR^1C(O)OR^2$, halogen, cyano, or nitro.

96. **(Previously Presented)** A method as in claim 91, wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

97. **(Previously Presented)** A method as in claim 93 wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

98. **(Previously Presented)** A method as in claim 94, wherein L^1 is phenyl or pyridinyl.

99. **(Previously Presented)** A method as in claim 95, wherein L^1 is phenyl or pyridinyl.

100. **(Previously Presented)** A method as in claim 97, wherein M is -O-, -S-, -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -O(CH_2)-, -S-(CH_2)-, -CHF-, -CF_2- or -C(O)CH_2-.

101. **(Previously Presented)** A method as in claim 98, wherein M is -O-, -S-, -C(O)-, -CH(OH)-, -(CH_2)O-, -(CH_2)S-, -O(CH_2)-, -CHF-, -CF_2-, -S-(CH_2)- or -C(O)CH_2-.

102. **(Previously Presented)** A method as in claim 99, wherein M is -O-, -S-, -(CH_2)O-, -(CH_2)S-, -O(CH_2)-, -CHF-, -CF_2-, -S-(CH_2)- or -C(O)CH_2-.

103. **(Previously Presented)** A method as in claim 91 wherein L^1 is substituted by -C(O)R_x.

104. **(Previously Presented)** A method of claim 100 wherein L^1 is substituted by -C(O)R_x wherein R_x is NR_aR_b.

105. **(Previously Presented)** A method as in claim 101 wherein L^1 is substituted by -C(O)R_x, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1-C_6 alkyl or C_1-C_6 alkoxy.

106. **(Previously Presented)** A method as in compound of claim 102 wherein L^1 is substituted by -C(O)R_x, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen, C_1-C_6 alkyl or C_1-C_6 alkoxy.

107. **(Currently Amended)** A method for the treatment of ~~a raf mediated disorder~~ cancerous cell growth mediated by raf kinase in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier, wherein

D is -NH-C(O)-NH-,

A is of the formula:

$$-L\text{-}M\text{-}L^1,$$

where L is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to per-halosubstituted alkyl, C_1-C_3 alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl up to per-halosubstituted alkyl, C_1-C_3 alkoxy, hydroxy, amino, C_1-C_3 alkylamino, C_1-C_6 dialkylamino, halogen, cyano, or nitro; and

M is one or more bridging groups which are -O-, -S-, $-N(R^7)$-, $-(CH_2)_m$-, -C(O)-, -CH(OH)-, $-(CH_2)_mO$-, $-(CH_2)_mS$-, $-(CH_2)_mN(R^7)$-, $-O(CH_2)_m$- CHX^a-, $-CX^a{}_2$-, $-S-(CH_2)_m$- or $-N(R^7)(CH_2)_m$-,

where each m is independently an integer of from 1-3, X^a is halogen, and

L^1 comprises a substituted cyclic moiety which is:

(i) naphthyl, optionally substituted with 1-3 substituents which are, independently, f R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(ii) 5 and 6 membered monocyclic heteroaryl groups, having 1-4 heteroatoms which are, independently, O, N or S, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

(iii) 8 to 10 membered bicyclic heteroaryl groups, having 1-6 heteroatoms, which are, independently, O, N or S, optionally substituted with 1-3 substituents, which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano or nitro;

wherein L^1 is substituted by one or more substituents which are $-SO_2R_x$, $-C(O)R_x$ or $-C(NR_y)\,R_z$,

wherein R_x independently chosen from the moieties of R_z or NR_aR_b and R_a and R_b are independently chosen from the moieties of R_z;

and

B is

(i) phenyl, optionally substituted with 1-3 substituents which are, independently, f R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro; or

(ii) pyridyl, optionally substituted with 1-3 substituents which are, independently, R^7, OR^7, $NR^7R^{7'}$, $C(O)R^7$, $C(O)OR^7$, $C(O)NR^7R^{7'}$, $NR^7C(O)R^{7'}$, $NR^7C(O)OR^{7'}$, halogen, cyano, or nitro;

each R_y is independently

(a) hydrogen,

(b) C_1-C_6 alkyl, optionally substituted with halogen up to per-halosubstitution,

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 halogen substituents,

(d) C_3-C_6 cyclic alkyl, optionally substituted with 1-3 halogen substituents,

(e) phenyl, optionally substituted with 1-3 halogen substituents,

(f) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 halogen substituents, or

(g) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 halogen substituents,

each R^7, $R^{7'}$ and R_z is independently

(a) hydrogen,

(b) C_1-C_6 linear, branched, or cyclic alkyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy or hydroxy;

(c) C_1-C_6 alkoxy, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy or halogen;

(d) phenyl, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(e) 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms which are N, S or O or 8-10 membered bicyclic heteroaryl having 1-6 heteroatoms which are N, S or O, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy or halogen,

(f) C_1-C_3 alkyl-phenyl, optionally substituted with 1-3 substituents, which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy, hydroxy or halogen; or

(g) up to per–halosubstituted C_1-C_5 linear, branched or cyclic alkyl, and where not per-halo substituted, optionally substituted with 1-3 substituents which are, independently, C_1-C_5 linear or branched alkyl, up to per-halosubstituted C_1-C_5 linear or branched alkyl, C_1-C_3 alkoxy or hydroxy.

108. (Previously Presented) A method as in claim 107 wherein substituents for B and L and additional substituents for L^1, one C_1-C_6 alkyl up to per-halosubstituted C_1-C_6 alkyl, CN, OH, halogen, C_1-C_6 alkoxy or up to per-halosubstituted C_1-C_6 alkoxy.

109. (Previously Presented) A method of claim 107 wherein L^1 is pyridyl and is substituted by $C(O)R_x$ or SO_2 NR_aR_b.

110. (Previously Presented) A method of claim 91 wherein a pharmaceutically acceptable salt of a compound of Formula I of claim 91 is used which is

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

111. **(Previously Presented)** A method of claim 107 wherein a pharmaceutically acceptable salt of a compound Formula I of claim 61 which is selected from the group consisting of

a) a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

112. **(Previously Presented)** A method of claim 91 wherein the substituted or unsubstituted monocyclic heteroaryl groups of B, L and L^1 are, independently,

2- and 3-furyl,

2- and 3-thienyl,

2- and 4-triazinyl,

1-, 2- and 3-pyrrolyl,

1-, 2-, 4- and 5-imidazolyl,

1-, 3-, 4- and 5-pyrazolyl,

2-, 4- and 5-oxazolyl,

3-, 4- and 5-isoxazolyl,

2-, 4- and 5-thiazolyl,

3-, 4- and 5-isothiazolyl,

2-, 3- and 4-pyridyl,

2-, 4-, 5- and 6-pyrimidinyl,

1,2,3-triazol-1-, -4- and –5-yl,

1,2,4-triazol-1-, -3- and –5-yl,

1- and 5-tetrazolyl,

1,2,3-oxadiazol-4- and –5-yl,

1,2,4-oxadiazol-3- and –5-yl,

1,3,4-thiadiazol-2- and –5-yl,

1,2,4-oxadiazol-3- and –5-yl,
1,3,4-thiadiazol-2- and –5-yl,
1,3,4-thiadiazol-3- and –5-yl,
1,2,3-thiadiazol-4- and –5-yl,
2-, 3-, 4-, 5- and 6-2H-thiopyranyl,
2-, 3- and 4-4H-thiopyranyl,
3- and 4-pyridazinyl, or
2-,3-pyrazinyl.

113. (Previously Presented) A method of claim 91 wherein the substituted or unsubstituted bicyclic heteroaryl groups of B and L^1 are, independently:
2-, 3-, 4-, 5-, 6- and 7-benzofuryl,
2-, 3-, 4-, 5-, 6- and 7-benzothienyl,
1-, 2-, 3-, 4-, 5-, 6- and 7-indolyl,
1-, 2-, 4- and 5-benzimidazolyl,
1-, 3-, 4-, 5-, 6- and 7-benzopyrazolyl,
2-, 4-, 5-, 6- and 7-benzoxazolyl,
3-, 4-, 5- 6- and 7-benzisoxazolyl,
1-, 3-, 4-, 5-, 6- and 7-benzothiazolyl,
2-, 4-, 5-, 6- and 7-benzisothiazolyl,
2-, 4-, 5-, 6- and 7-benz-1,3-oxadiazolyl,
2-, 3-, 4-, 5-, 6-, 7- and 8-quinolinyl,
1-, 3-, 4-, 5-, 6-, 7-, and 8- isoquinolinyl,
2-, 4-, 5-, 6-, 7- and 8-quinazolinyl,
tetrahydroquinolinyl,
tetrahydroisoquinolinyl,
dihydrobenzofuryl,
pyrazolo[3,4-b]pyrimidinyl,
purinyl,
benzodiazine,
pterindinyl,
pyrrolo[2,3-b]pyridinyl,
pyrazolo[3,4-b]pyridinyl,

oxazo[4,5-b]pyridinyl,
imidazo[4,5-b]pyridinyl,
cyclopentenopyridine,
cyclohexanopyridine,
cyclopentanopyrimidine,
cyclohexanopyrimidine,
cyclcopentanopyrazine,
cyclohexanopyrazine,
cyclopentanopyridiazine,
cyclohexanopyridazine,
cyclopentanoimidazole,
cyclohexanoimidazole,
cyclopentanothiophen or
cyclohexanothiophene.

114. (Previously Presented) A method of claim 91 wherein the substituted 5 and 6 membered monocyclic heteroaryl moieties of **B**, **L** and L^1 are independently

5-methyl-2-thienyl,
4-methyl-2-thienyl,
1-methyl-3-pyrolyl,
1-methyl-3-pyrazolyl,
5-methyl-2-thiazolyl, or
5-methyl-1,2,4-thiadiazol-2-yl; or

the substituted phenyl and naphthyl groups of **B**, **L** and L^1 are independently

tetrahydronaphthyl,
indanyl,
indenyl,
benzocyclobutanyl,
benzocycloheptanyl or
benzocycloheptenyl;

the partially saturated monocyclic heterocyclic moieties of **B**, **L** and L^1 are independently:

dihydropyranyl,
dihydrofuranyl,

dihydrothienyl,
dihydropiperidinyl or
dihydropyrimidonyl.

115. (Previously Presented) A method of claim 91 wherein the structures of B, L and L^1 are each,

phenyl, furyl,
oxadiazolyl, oxazolyl, isooxazolyl,
pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl,
tetrazolyl,
thiadiazolyl, thiazolyl or thienyl and
the structures of B and L^1 are additionally naphthyl, isoindolinyl, quinolinyl or isoquinolinyl.

116. (Previously Presented) A method of claim 115 wherein the substituents of the substituted structures of L are methyl, triflouromethyl, ethyl, n-propyl, n-butyl, n-pentyl, i-propyl, t-butyl, methoxy, ethoxy, propoxy, Cl, Br, F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino or diethylamino.

117. (Previously Presented) A method of claim 115 wherein the substituents of the substituted structures of B and L^1 are methyl, triflouromethyl, ethyl, n-propyl, n-butyl, n-pentyl, isopropyl, *tert*-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, Cl, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino or diethylamino.

118. (Previously Presented) A method of claim 115 wherein the substituents of the substituted structures of B and L^1 are each, independently, selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, chlorophenyl, dichlorophenyl, bromophenyl, dibromophenyl, chloropyridinyl, bromopyridinyl, dichloropyridinyl, dibromopyridinyl methylphenyl, methylpyridinyl quinolinyl, isoquinolinyl, isoindolinyl, pyrazinyl, pyridazinyl, pyrrolinyl, imidazolinyl, thienyl, furyl, isoxazolinyl, isothiazolinyl, benzopyridinyl, benzothiazolyl,
C_1-C_5 acyl;

$NH(C_1\text{-}C_5$ alkyl, phenyl or pyridinyl);
$N(C_1\text{-}C_5$ alkyl)($C_1\text{-}C_5$ alkyl, phenyl or pyridinyl);
$N(C_1\text{-}C_3$ alkyl) $SO_2(C_1\text{-}C_5$ alkyl);
$CO(C_1\text{-}C_6$ alkyl or phenyl);
C(O)H;
$C(O)O(C_1\text{-}C_6$ alkyl or phenyl);
C(O)OH;
$C(O)NH_2$;
$C(O)NH(C_1\text{-}C_6$ alkyl or phenyl);
$C(O)N(C_1\text{-}C_6$ alkyl or phenyl)($C_1\text{-}C_6$ alkyl, phenyl or pyridinyl);
$C(NCH_3)CH_3$;
$NHC(O)(C_1\text{-}C_6$ alkyl or phenyl) or
$N(C_1\text{-}C_5$ alkyl,)$C(O)(C_1\text{-}C_5$ alkyl).

119. (Previously Presented) A method as in claim 91 wherein B, L and L^1 of the compound of Formula I or the pharmaceutically acceptable salt thereof follow one of the following of combinations:
B= phenyl, L=phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= phenyl, L=pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=phenyl, L = naphthyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=pyridinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B=pyridinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B =isoquinolinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= isoquinolinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl,
B= quinolinyl, L= phenyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl, or
B= quinolinyl, L= pyridinyl and L^1 is phenyl, pyridinyl, quinolinyl or isoquinolinyl.

120. (Previously Presented) A method as in claim 119 wherein the pharmaceutically acceptable salt is

a) a basic salt of an organic acid or an inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic

acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or mandelic acid; or

b) an acid salt of an organic or inorganic base containing an alkali metal cation, an alkaline earth metal cation, an ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

121. (Previously Presented) A method for the treatment of cancerous cell growth mediated by raf kinase in a human or other mammal, comprising administering to a human or other mammal in need thereof, a pharmaceutical composition comprising a tosylate salt of

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-carbamoyl-4-pyridyloxy)phenyl) urea or

N-(4-chloro-3-(trifluoromethyl)phenyl)-*N'*-(4-(2-(*N*-methylcarbamoyl)-4-pyridyloxy)phenyl) urea.